Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-TIM-3 Blocked RAK Cells for HCC Recurrence
NCT05738980Recruiting
- Sponsor
- Beijing Hospital
- Start
- Feb 2023
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Randomised trial in hepatocellular carcinoma (HCC) (2 arms), sponsored by Beijing Hospital. Primary endpoint: Recurrence-Free Survival at 2 years. Started Feb 2023; status: recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05738980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05738980.